Bjørn Tore Gjertsen • 1966 • Morvik • 7 roles • 7 shareholdings

This website uses cookies to enhance the user experience.

Roles

Management

Name	Role	Total operating income	Total equity	Shares
T TRES BIOTECHNOLOGY AS	Managing Director/CEO	27,760	47,309	50 % directly

Boards

Name	Role	Total operating income	Total equity	Shares
H HÁ BIOTECH AS	Board Member	-	42,897	66 % directly
K KINN THERAPEUTICS AS	Deputy Chair	3,158,893	547,060	50 % directly
T TRES BIOTECHNOLOGY AS	Chairman	27,760	47,309	50 % directly
Y YZ HOLDING AS	Deputy Chair	29,000	264,820	40 % directly
A ALDEN CANCER THERAPY AS	Deputy Chair	-	-897,729	23.57 % indirectly
B BJØRGVIN THERAPEUTICS GROUP AS	Board Member	-	-	-

Last update: Apr 5, 2024

Related industries3

Professional, scientific and technical activities
Manufacturing
Administrative and support service activities

Direct relationships5

KH
Karl Henning Kalland1955
ALDEN CANCER THERAPY AS, YZ HOLDING AS
AM
Anne Margrete Øyan1949
ALDEN CANCER THERAPY AS, YZ HOLDING AS
ØE
Øivind Enger1956
HÁ BIOTECH AS
MS
Marcel Sandberg1969
BJØRGVIN THERAPEUTICS GROUP AS
SK
Stener Kvinnsland1948
ALDEN CANCER THERAPY AS

Shares owned by Bjørn Tore Gjertsen

Name	Share class	Total operating income	Total equity	Share
H HÁ BIOTECH AS	Ordinære aksjer	0	42,897	66 % directly
T TRES BIOTECHNOLOGY AS	Ordinære aksjer	27,760	47,309	50 % directly
K KINN THERAPEUTICS AS	Ordinære aksjer	3,158,893	547,060	50 % directly
Y YZ HOLDING AS	Ordinære aksjer	29,000	264,820	40 % directly
A ALDEN CANCER THERAPY AS		0	-897,729	23.57 % indirectly
L LEDIDI AS	Ordinære aksjer	2,169,575	2,507,181	< 0.01 % directly
B BERGENBIO ASA	NO0010650013	1,036,000	126,828,000	< 0.01 % directly

Limited to direct ownership positions of 0.5% or more.

Last update: May 24, 2024